AOR

The Archives of Ophthalmological Research aims to publish issues related to publish articles of the highest scientific and clinical value at an international level, and accepts articles on these topics. The target audience of the journal included specialists and physicians working in ophthalmology, and other health professionals interested in these fields.

EndNote Style
Index
Case Report
Ophthalmologic evaluation and management of early adult-onset classic myotonic dystrophy type 1: a case report
Myotonic dystrophy type 1 (DM1) is an autosomal dominant disease with variable age of onset and clinical severity, involving not only the musculoskeletal system but also multiple organs including the eyes, heart, lungs, and endocrine system. A 28-year-old woman with a known diagnosis of DM1 presented with blurred vision. Ophthalmologic examination revealed bilateral blepharoptosis, hatchet-face appearance, nuclear sclerosis, and early Christmas-tree cataract with polychromatic refractile opacities. Fundus examination demonstrated hyperpigmented macular changes, while optical coherence tomography showed retinal pigment epithelial irregularities, reticular pigmentary abnormalities, mild epiretinal membrane, and increased macular thickness. Family history revealed affected father and severe congenital involvement in deceased male siblings, suggesting anticipation. Systemic evaluation showed mild intellectual disability and muscle involvement without current cardiac arrhythmia. The patient was referred for multidisciplinary follow-up including neurology, cardiology, pulmonology, and internal medicine. This case highlights the importance of ophthalmologic evaluation in recognizing early DM1 and its multisystemic involvement.


1. Hartman J, Patki T, Johnson NE. Diagnosis and management of myotonic dystrophy type 1. JAMA. 2024;331(14):1227-1228. doi:10.1001/jama.2024.2511
2. Ikeda KS, Iwabe-Marchese C, França Jr MC, Nucci A, de Carvalho KM. Myotonic dystrophy type 1: frequency of ophthalmologic findings. Arq Neuropsiquiatr. 2016;74(3):183-188. doi:10.1590/0004-282X20150218
3. Bird TD. Myotonic Dystrophy Type 1. University of Washington, Seattle, Seattle (WA); 1993.
4. Chahine M, Ginjupalli VKM, Jauvin D, Boutjdir M. Therapeutic strategies targeting the molecular pathogenesis of myotonic dystrophy type 1: current status and future directions. Mol Diagn Ther. 2026. doi:10.1007/s40291-026-00848-3
5. Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81(4):358-367. doi:10.1136/jnnp.2008.158261
6. Rahm L, Hale MA, Raaijmakers RHL, et al. Myotonic dystrophy type 1: clinical diversity, molecular insights and therapeutic perspectives. Nat Rev Neurol. 2025;21(11):623-641. doi:10.1038/s41582-025-01139-x
7. Abed E, D’Amico G, Rossi S, Perna A, Bianchi MLE, Silvestri G. Spectral domain optical coherence tomography findings in myotonic dystrophy. Neuromuscular Disorders. 2020;30(2):144-150. doi:10.1016/j.nmd.2019.11.012
8. Vasilijevic J, Peric S, Basta I, et al. Retinal vascular abnormalities in myotonic dystrophy assessed by optical coherence tomography angiography-cross-sectional study. Eur J Ophthalmol. 2025;35(1):262-268. doi:10.1177/11206721241247424
9. Akan O, Erden B. Optical coherence tomography findings in patients with myotonic dystrophy type 1. Eur Arch Med Res. 2021;37(3):178-182. doi:10.4274/eamr.galenos.2021.53315
10. Ginjupalli VKM, Reisqs JB, Cupelli M, Chahine M, Boutjdir M. Cardiac involvement in myotonic dystrophy type 1: mechanisms, clinical perspectives, and emerging therapeutic strategies. Int J Mol Sci. 2025; 26(22):10992. doi:10.3390/ijms262210992
Volume 3, Issue 2, 2026
Page : 28-30
_Footer